Overview

Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cisplatin
Gefitinib